Beneficial effects of growth hormone-releasing peptide on myocardial oxidative stress and left ventricular dysfunction in dilated cardiomyopathic hamsters.

Kato Y, Iwase M, Ichihara S, Kanazawa H, Hashimoto K, Noda A, Nagata K, Koike Y, Yokota M

Circulation journal : official journal of the Japanese Circulation Society27 Nov 2009Cited by 12 (Europe PMC)

PMID19942785DOI10.1253/circj.cj-09-0378PepBankPUB-19942785

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In cardiomyopathic TO-2 hamsters, GHRP‑2 attenuated the progression of left ventricular remodeling versus saline.
In plain wordsIn hamsters with heart muscle disease, GHRP‑2 slowed worsening of heart chamber remodeling compared with saline.
Peptide
GHRP-2
Outcome
DecreaseProgression of LV remodeling
Study
hamstern: not reported in source
Dilated cardiomyopathic TO-2 hamsters
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
1 mg/kg · 6 to 12 weeks of ageAs given in this study (hamster).
Source sentences
Summary
Treatment with GHRP-2 attenuated the progression of LV remodeling and dysfunction, as well as myocardial fibrosis, in TO-2 hamsters.
1 context sentence(design, population, supporting numbers)
Summary · context
Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age.
Report a problemFND-1994278501
02AnimalAnimal study (in vivo)Efficacy outcome
In cardiomyopathic TO-2 hamsters, GHRP‑2 attenuated the progression of left ventricular dysfunction versus saline.
In plain wordsIn hamsters with heart muscle disease, GHRP‑2 slowed worsening of heart pumping function compared with saline.
Peptide
GHRP-2
Outcome
DecreaseProgression of LV dysfunction
Study
hamstern: not reported in source
Dilated cardiomyopathic TO-2 hamsters
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
1 mg/kg · 6 to 12 weeks of ageAs given in this study (hamster).
Source sentences
Summary
Treatment with GHRP-2 attenuated the progression of LV remodeling and dysfunction, as well as myocardial fibrosis, in TO-2 hamsters.
1 context sentence(design, population, supporting numbers)
Summary · context
Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age.
Report a problemFND-1994278502
03AnimalAnimal study (in vivo)Efficacy outcome
In cardiomyopathic TO-2 hamsters, GHRP‑2 attenuated myocardial fibrosis versus saline.
In plain wordsIn hamsters with heart muscle disease, GHRP‑2 reduced scarring in the heart muscle compared with saline.
Peptide
GHRP-2
Outcome
DecreaseMyocardial fibrosis
Study
hamstern: not reported in source
Dilated cardiomyopathic TO-2 hamsters
Comparator
Saline
Outcome group
Heart function · Cardiovascular
Studied dose
1 mg/kg · 6 to 12 weeks of ageAs given in this study (hamster).
Source sentences
Summary
Treatment with GHRP-2 attenuated the progression of LV remodeling and dysfunction, as well as myocardial fibrosis, in TO-2 hamsters.
1 context sentence(design, population, supporting numbers)
Summary · context
Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age.
Report a problemFND-1994278503
04AnimalAnimal study (in vivo)Efficacy outcome
In cardiomyopathic TO-2 hamsters, GHRP‑2 inhibited the decrease in the myocardial GSH/GSSG ratio.
In plain wordsIn hamsters with heart muscle disease, GHRP‑2 prevented the fall in a heart marker of antioxidant balance.
Peptide
GHRP-2
Outcome
IncreaseMyocardial GSH/GSSG ratio
Study
hamstern: not reported in source
Dilated cardiomyopathic TO-2 hamsters
Comparator
Saline
Outcome group
Oxidative stress · Cardiovascular
Studied dose
1 mg/kg · 6 to 12 weeks of ageAs given in this study (hamster).
Source sentences
Summary
GHRP-2 also inhibited both the decrease in the GSH/GSSG ratio and the increase in the concentration of 4-HNE in the hearts of TO-2 hamsters.
1 context sentence(design, population, supporting numbers)
Summary · context
Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age.
Report a problemFND-1994278504
05AnimalAnimal study (in vivo)Efficacy outcome
In cardiomyopathic TO-2 hamsters, GHRP‑2 inhibited the increase in myocardial 4-HNE concentration.
In plain wordsIn hamsters with heart muscle disease, GHRP‑2 prevented the rise in a heart marker of oxidative damage.
Peptide
GHRP-2
Outcome
DecreaseMyocardial 4-HNE concentration
Study
hamstern: not reported in source
Dilated cardiomyopathic TO-2 hamsters
Comparator
Saline
Outcome group
Oxidative stress · Cardiovascular
Studied dose
1 mg/kg · 6 to 12 weeks of ageAs given in this study (hamster).
Source sentences
Summary
GHRP-2 also inhibited both the decrease in the GSH/GSSG ratio and the increase in the concentration of 4-HNE in the hearts of TO-2 hamsters.
1 context sentence(design, population, supporting numbers)
Summary · context
Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age.
Report a problemFND-1994278505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.